Cargando…

Re: Implication of low‐dose sacubitril/valsartan

Detalles Bibliográficos
Autores principales:	Pandey, Amitabh C., Heywood, James Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943907/ https://www.ncbi.nlm.nih.gov/pubmed/33570218 http://dx.doi.org/10.1002/clc.23560

Ejemplares similares

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N‐terminal pro B‐type natriuretic peptide levels
por: Pandey, Amitabh C., et al.
Publicado: (2020)

Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
por: Bocchi, Edimar Alcides, et al.
Publicado: (2018)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
por: Mohebi, Reza, et al.
Publicado: (2023)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Successful treatment of doxorubicin-induced cardiomyopathy with low-dose sacubitril/valsartan: a case report
por: Bell, Elisabeth, et al.
Publicado: (2022)

A New Approach for Hypertension: the Case of Sacubitril/Valsartan Experienced in Randomized Controlled Trials That Selectively Restrict Its Use to the Hypertension of the Elderly
por: De Vecchis, Renato, et al.
Publicado: (2018)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
por: Vilela-Martin, José Fernando
Publicado: (2016)

Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis
por: Kim, Hyoeun, et al.
Publicado: (2021)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
por: Ding, Ying, et al.
Publicado: (2023)

Efficacy and safety of low‐dose sacubitril/valsartan in heart failure patients: A systematic review and meta‐analysis
por: Chen, Wen‐Wen, et al.
Publicado: (2023)

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
por: Lo, Shih-Hsing, et al.
Publicado: (2021)

Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension: A case report
por: Feng, Yunlin, et al.
Publicado: (2022)

Effect of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide
por: Ayalasomayajula, Surya, et al.
Publicado: (2018)

Drug-Induced Liver Injury From Sacubitril-Valsartan Versus a Single Dose of Acarbose
por: Achuthanandan, Supraja, et al.
Publicado: (2022)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
por: Visco, Valeria, et al.
Publicado: (2022)

Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hsieh, Hui-Ling, et al.
Publicado: (2021)

Renal protection in chronic heart failure: focus on sacubitril/valsartan
por: Pontremoli, Roberto, et al.
Publicado: (2021)

Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure
por: Bano, Shehar, et al.
Publicado: (2021)

Bendroflumethiazide/sacubitril/valsartan: Hyperkalaemia and hyponatraemia: 8 case reports
Publicado: (2021)

Metoprolol/sacubitril/valsartan/spironolactone: Lack of efficacy: case report
Publicado: (2021)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Valsartan/Sacubitril in heart failure and hypotension: how, when and why
por: Scardovi, Angela Beatrice, et al.
Publicado: (2019)

A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan
por: Rawla, Prashanth, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7a6q9mhf1iqo3858bhqn2189a8